留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景

李慧 杨志

李慧, 杨志. 前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景[J]. 协和医学杂志, 2022, 13(2): 192-198. doi: 10.12290/xhyxzz.2021-0492
引用本文: 李慧, 杨志. 前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景[J]. 协和医学杂志, 2022, 13(2): 192-198. doi: 10.12290/xhyxzz.2021-0492
LI Hui, YANG Zhi. Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 192-198. doi: 10.12290/xhyxzz.2021-0492
Citation: LI Hui, YANG Zhi. Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 192-198. doi: 10.12290/xhyxzz.2021-0492

前列腺特异性膜抗原PET/MRI在前列腺癌中的应用现状与前景

doi: 10.12290/xhyxzz.2021-0492
基金项目: 

北京大学肿瘤医院科学研究基金 2020-17

详细信息
    通讯作者:

    杨志,E-mail:pekyz@163.com

  • 中图分类号: R445; R-1

Prostate Specific Membrane Antigen PET/MRI for the Management of Prostate Cancer: Current Status and Future Directions

Funds: 

Science Foundation of Peking University Cancer Hospital 2020-17

More Information
  • 摘要: 前列腺癌(prostate cancer, PCa)是常见的老年男性恶性肿瘤,并是其主要致死原因之一。前列腺特异性膜抗原(prostate specific membrane antigen, PSMA)是一种PCa组织特异性高表达的跨膜蛋白,这使得PSMA成为PCa良好的特异性分子影像靶点。目前,PSMA PET/CT在PCa诊断、分期等方面的价值已被广泛认可。随着PET/MRI逐步进入临床,PSMA PET与MRI两种诊断PCa的重要影像学方法的有机结合成为可能。本文就PSMA PET/MRI在PCa中的应用现状与前景进行阐述,以期为临床诊疗提供借鉴。
    作者贡献:李慧负责查阅文献和论文撰写;杨志负责修订和审校论文。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older, 2019[J]. CA Cancer J Clin, 2019, 69: 452-467. doi:  10.3322/caac.21577
    [2] Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71: 7-33. doi:  10.3322/caac.21654
    [3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68: 394-424. doi:  10.3322/caac.21492
    [4] 付振涛, 郭晓雷, 张思维, 等. 2015年中国前列腺癌发病与死亡分析[J]. 中华肿瘤杂志, 2020, 42: 718-722. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201211003.htm

    Fu ZT, Guo XL, Zhang SW, et al. Statistical analysis of incidence and mortality of prostate cancer in China, 2015[J]. Zhonghua Zhongliu Zazhi, 2020, 42: 718-722. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201211003.htm
    [5] 李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J]. 肿瘤防治研究, 2021, 48: 98-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202101019.htm

    Li X, Zeng XY. Advances in Epidemiology of Prostate Cancer in China[J]. Zhongliu Fangzhi Yanjiu, 2021, 48: 98-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLFY202101019.htm
    [6] 顾秀瑛, 郑荣寿, 张思维, 等. 2000—2014年中国肿瘤登记地区前列腺癌发病趋势及年龄变化分析[J]. 中华预防医学杂志, 2018, 52: 586-592.

    Gu XY, Zheng RS, Zhang SW, et al. Analysis on the trend of prostate cancer incidence and age change in cancer registration areas of China, 2000 to 2014[J]. Zhonghua Yufang Yixue Zazhi, 2018, 52: 586-592.
    [7] Hoffmann MA, Wieler HJ, Baues C, et al. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer[J]. Urology, 2019, 130: 1-12. doi:  10.1016/j.urology.2019.04.004
    [8] Muller BG, Shih JH, Sankineni S, et al. Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging[J]. Radiology, 2015, 277: 741-750. doi:  10.1148/radiol.2015142818
    [9] 熊诗诗, 吴介恒, 韩东晖, 等. 针对前列腺特异性膜抗原的抗体靶向治疗研究进展[J]. 细胞与分子免疫学杂志, 2017, 33: 278-282. https://www.cnki.com.cn/Article/CJFDTOTAL-XBFM201702029.htm
    [10] Fendler WP, Calais J, Eiber M, et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial[J]. JAMA Oncol, 2019, 5: 856-863. doi:  10.1001/jamaoncol.2019.0096
    [11] Calais J, Ceci F, Eiber M, et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial[J]. Lancet Oncol, 2019, 20: 1286-1294. doi:  10.1016/S1470-2045(19)30415-2
    [12] Liu C, Liu T, Zhang N, et al. (68)Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 1852-1861. doi:  10.1007/s00259-018-4037-9
    [13] Afshar-Oromieh A, Haberkorn U, Hadaschik B, et al. PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2013, 40: 1629-1630. doi:  10.1007/s00259-013-2489-5
    [14] 卢洁, 张苗, 方继良, 等. 一体化PET/MR颅脑成像检查规范(2017版)[J]. 中国医学影像技术, 2017, 33: 791-794. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201705050.htm

    Lu J, Zhang M, Fang JL, et al. Guidelines for hybrid PET/MR in brain imaging (2017 Edition)[J]. Zhongguo Yixue Yingxiang Jishu, 2017, 33: 791-794. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYXX201705050.htm
    [15] Hoeks CM, Barentsz JO, Hambrock T, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging[J]. Radiology, 2011, 261: 46-66. doi:  10.1148/radiol.11091822
    [16] Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis[J]. N Engl J Med, 2018, 378: 1767-1777. doi:  10.1056/NEJMoa1801993
    [17] Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study[J]. Lancet, 2017, 389: 815-822. doi:  10.1016/S0140-6736(16)32401-1
    [18] Hamoen EHJ, de Rooij M, Witjes JA, et al. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis[J]. Eur Urol, 2015, 67: 1112-1121. doi:  10.1016/j.eururo.2014.10.033
    [19] Lee T, Hoogenes J, Wright I, et al. Utility of preoperative 3 Tesla pelvic phased-array multiparametric magnetic resonance imaging in prediction of extracapsular extension and seminal vesicle invasion of prostate cancer and its impact on surgical margin status: Experience at a Canadian academic tertiary care centre[J]. Can Urol Assoc J, 2017, 11: E174-E178. doi:  10.5489/cuaj.4211
    [20] Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues[J]. Clin Cancer Res, 1997, 3: 81-85.
    [21] Eiber M, Weirich G, Holzapfel K, et al. Simultaneous (68)Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer[J]. Eur Urol, 2016, 70: 829-836. doi:  10.1016/j.eururo.2015.12.053
    [22] Uprimny C, Kroiss AS, Decristoforo C, et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 941-949. doi:  10.1007/s00259-017-3631-6
    [23] Wang R, Shen G, Yang R, et al. (68)Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis[J]. Eur J Radiol, 2020, 130: 109131. doi:  10.1016/j.ejrad.2020.109131
    [24] Al-Bayati M, Grueneisen J, Lütje S, et al. Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging[J]. Urol Int, 2018, 100: 164-171. doi:  10.1159/000484695
    [25] Thalgott M, Düwel C, Rauscher I, et al. One-Stop-Shop Whole-Body (68)Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer[J]. J Nucl Med, 2018, 59: 1850-1856. doi:  10.2967/jnumed.117.207696
    [26] Chen M, Zhang Q, Zhang C, et al. Combination of (68)Ga-PSMA PET/CT and Multiparametric MRI Improves the Detection of Clinically Significant Prostate Cancer: A Lesion-by-Lesion Analysis[J]. J Nucl Med, 2019, 60: 944-949. doi:  10.2967/jnumed.118.221010
    [27] Muehlematter UJ, Burger IA, Becker AS, et al. Diagnostic Accuracy of Multiparametric MRI versus (68)Ga-PSMA-11 PET/MRI for Extracapsular Extension and Seminal Vesicle Invasion in Patients with Prostate Cancer[J]. Radiology, 2019, 293: 350-358. doi:  10.1148/radiol.2019190687
    [28] Grubmüller B, Baltzer P, Hartenbach S, et al. PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact[J]. Clin Cancer Res, 2018, 24: 6300-6307. doi:  10.1158/1078-0432.CCR-18-0768
    [29] Fendler WP, Schmidt DF, Wenter V, et al. 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer[J]. J Nucl Med, 2016, 57: 1720-1725. doi:  10.2967/jnumed.116.172627
    [30] Domachevsky L, Bernstine H, Goldberg N, et al. Comparison between pelvic PSMA-PET/MR and whole-body PSMA-PET/CT for the initial evaluation of prostate cancer: a proof of concept study[J]. Eur Radiol, 2020, 30: 328-336. doi:  10.1007/s00330-019-06353-y
    [31] Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis[J]. Clin Radiol, 2008, 63: 387-395. doi:  10.1016/j.crad.2007.05.022
    [32] Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer[J]. J Urol, 2016, 195: 1436-1443. doi:  10.1016/j.juro.2015.12.025
    [33] Uslu-Beşli I, Bakl B, Asa S, et al. Correlation of SUV(max) and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study[J]. Mol Imaging Radionucl Ther, 2019, 28: 104-111. doi:  10.4274/mirt.galenos.2019.63825
    [34] Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and (68)Ga-PSMA PET for skeletal staging in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43: 2114-2121. doi:  10.1007/s00259-016-3435-0
    [35] Roach PJ, Francis R, Emmett L, et al. The Impact of (68)Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study[J]. J Nucl Med, 2018, 59: 82-88. doi:  10.2967/jnumed.117.197160
    [36] Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience[J]. Eur J Nucl Med Mol Imaging, 2014, 41: 887-897. doi:  10.1007/s00259-013-2660-z
    [37] Ferraro DA, Becker AS, Kranzbühler B, et al. Diagnostic performance of 68Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study[J]. Eur J Nucl Med Mol Imaging, 2021, 48: 3315-3324. doi:  10.1007/s00259-021-05261-y
    [38] Lindenberg ML, Turkbey B, Mena E, et al. Imaging Locally Advanced, Recurrent, and Metastatic Prostate Cancer: A Review[J]. JAMA Oncol, 2017, 3: 1415-1422. doi:  10.1001/jamaoncol.2016.5840
    [39] Suardi N, Gandaglia G, Gallina A, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years[J]. Eur Urol, 2015, 67: 299-309. doi:  10.1016/j.eururo.2014.02.011
    [40] Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy[J]. J Nucl Med, 2015, 56: 668-674. doi:  10.2967/jnumed.115.154153
    [41] Hijazi S, Meller B, Leitsmann C, et al. See the unseen: Mesorectal lymph node metastases in prostate cancer[J]. Prostate, 2016, 76: 776-780. doi:  10.1002/pros.23168
    [42] Kranzbühler B, Nagel H, Becker AS, et al. Clinical performance of (68)Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy[J]. Eur J Nucl Med Mol Imaging, 2018, 45: 20-30. doi:  10.1007/s00259-017-3850-x
    [43] Kranzbühler B, Müller J, Becker AS, et al. Detection Rate and Localization of Prostate Cancer Recurrence Using (68)Ga-PSMA-11 PET/MRI in Patients with Low PSA Values ≤ 0.5 ng/mL[J]. J Nucl Med, 2020, 61: 194-201. doi:  10.2967/jnumed.118.225276
    [44] Joshi A, Roberts MJ, Perera M, et al. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial[J]. Clin Exp Metastasis, 2020, 37: 551-560. doi:  10.1007/s10585-020-10043-1
    [45] Freitag MT, Radtke JP, Afshar-Oromieh A, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in (68)Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI[J]. Eur J Nucl Med Mol Imaging, 2017, 44: 776-787. doi:  10.1007/s00259-016-3594-z
    [46] Guberina N, Hetkamp P, Ruebben H, et al. Whole-Body Integrated[(68)Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference[J]. Mol Imaging Biol, 2020, 22: 788-796. doi:  10.1007/s11307-019-01424-4
    [47] Turkbey B, Brown AM, Sankineni S, et al. Multipara-metric prostate magnetic resonance imaging in the evaluation of prostate cancer[J]. CA Cancer J Clin, 2016, 66: 326-336. doi:  10.3322/caac.21333
    [48] Abufaraj M, Grubmüller B, Zeitlinger M, et al. Prospec-tive evaluation of the performance of[(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy[J]. Eur J Nucl Med Mol Imaging, 2019, 46: 2169-2177. doi:  10.1007/s00259-019-04361-0
    [49] Vargas HA, Wassberg C, Akin O, et al. MR imaging of treated prostate cancer[J]. Radiology, 2012, 262: 26-42. doi:  10.1148/radiol.11101996
    [50] Hötker AM, Mazaheri Y, Zheng J, et al. Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI[J]. Eur Radiol, 2015, 25: 2665-2672. doi:  10.1007/s00330-015-3688-1
    [51] Eisenhauer EA, Therasse P, Bogaerts J, et al. New res-ponse evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45: 228-247. doi:  10.1016/j.ejca.2008.10.026
    [52] Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate[J]. Br J Cancer, 2009, 101: 1225-1232. doi:  10.1038/sj.bjc.6605334
    [53] Barbosa FG, Queiroz MA, Nunes RF, et al. Clinical perspectives of PSMA PET/MRI for prostate cancer[J]. Clinics (Sao Paulo), 2018, 73: e586s.
    [54] Burger IA, Müller J, Donati OF, et al. (68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU[J]. J Nucl Med, 2019, 60: 1118-1123. doi:  10.2967/jnumed.118.221564
  • 加载中
计量
  • 文章访问数:  136
  • HTML全文浏览量:  23
  • PDF下载量:  45
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-06-25
  • 录用日期:  2021-10-21
  • 网络出版日期:  2021-10-26
  • 刊出日期:  2022-03-30

目录

    /

    返回文章
    返回